To appraise the clinical and cost-effectiveness of Nivolumab in combination with relatlimab within its marketing authorisation for melanoma
 
Status In progress
Process STA 2018
ID number 1612

Timeline

Key events during the development of the guidance:

Date Update
08 May 2019 In progress, Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance